Regulatory polymorphism in transcription factor KLF5 at the MEF2 element alters the response to angiotensin II and is associated with human hypertension

FASEB Journal

Volumn 24, Issue 6, 2010, Pages 1780-1788

  Oishi, Yumiko ^a   Manabe, Ichiro ^a,b   Imai, Yasushi ^a   Hara, Kazuo ^a   Horikoshi, Momoko ^a   Fujiu, Katsuhito ^a   Tanaka, Toshihiro ^c   Aizawa, Tadanori ^d   Kadowaki, Takashi ^a   Nagai, Ryozo ^a,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c RIKEN   (Japan)

^d THE CARDIOVASCULAR INSTITUTE   (Japan)

^e UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

p38 MAP kinase; Reactive oxygen species

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANGIOTENSIN II; KRUPPEL LIKE FACTOR 5; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOCYTE ENHANCER FACTOR 2; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

ADULT; AGED; ANIMAL CELL; AORTA MEDIA; ARTICLE; BINDING AFFINITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; ENZYME ACTIVITY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II; ANIMALS; AORTA; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MADS DOMAIN PROTEINS; MALE; MIDDLE AGED; MYOGENIC REGULATORY FACTORS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RATS; REACTIVE OXYGEN SPECIES; RESPONSE ELEMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 77953528432     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.09-146589     Document Type: Article

References (35)

1. Shindo, T., Manabe, I., Fukushima, Y., Tobe, K., Aizawa, K., Miyamoto, S., Kawai-Kowase, K., Moriyama, N., Imai, Y., Kawakami, H., Nishimatsu, H., Ishikawa, T., Suzuki, T., Morita, H., Maemura, K., Sata, M., Hirata, Y., Komukai, M., Kagechika, H., Kadowaki, T., Kurabayashi, M., and Nagai, R. (2002) Krüppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat. Med. 8, 856-863
2. Manabe, I., and Nagai, R. (2003) Regulation of smooth muscle phenotype. Curr. Atheroscler. Rep. 5, 214-222
3. Owens, G. K., Kumar, M. S., and Wamhoff, B. R. (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84, 767-801
4. Fujiu, K., Manabe, I., Ishihara, A., Oishi, Y., Iwata, H., Nishimura, G., Shindo, T., Maemura, K., Kagechika, H., Shudo, K., and Nagai, R. (2005) Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circ. Res. 97, 1132-1141
5. Hoshino, Y., Kurabayashi, M., Kanda, T., Hasegawa, A., Sakamoto, H., Okamoto, E., Kowase, K., Watanabe, N., Manabe, I., Suzuki, T., Nakano, A., Takase, S., Wilcox, J. N., and Nagai, R. (2000) Regulated expression of the BTEB2 transcription factor in vascular smooth muscle cells: analysis of developmental and pathological expression profiles shows implications as a predictive factor for restenosis. Circulation 102, 2528-2534
6. Kawai-Kowase, K., Kurabayashi, M., Hoshino, Y., Ohyama, Y., and Nagai, R. (1999) Transcriptional activation of the zinc finger transcription factor BTEB2 gene by Egr-1 through mitogen-activated protein kinase pathways in vascular smooth muscle cells. Circ. Res. 85, 787-795 (Pubitemid 29504153)
7. Potthoff, M. J., and Olson, E. N. (2007) MEF2: a central regulator of diverse developmental programs. Development 134, 4131-4140
8. Lin, Q., Lu, J., Yanagisawa, H., Webb, R., Lyons, G. E., Richardson, J. A., and Olson, E. N. (1998) Requirement of the MADSbox transcription factor MEF2C for vascular development. Development 125, 4565-4574 (Pubitemid 28564299)
9. Suzuki, E., Nishimatsu, H., Satonaka, H., Walsh, K., Goto, A., Omata, M., Fujita, T., Nagai, R., and Hirata, Y. (2002) Angiotensin II induces myocyte enhancer factor 2- and calcineurin/nuclear factor of activated T cell-dependent transcriptional activation in vascular myocytes. Circ. Res. 90, 1004-1011
10. Suzuki, E., Satonaka, H., Nishimatsu, H., Oba, S., Takeda, R., Omata, M., Fujita, T., Nagai, R., and Hirata, Y. (2004) Myocyte enhancer factor 2 mediates vascular inflammation via the p38-dependent pathway. Circ. Res. 95, 42-49
11. Katoh, Y., Molkentin, J. D., Dave, V., Olson, E. N., and Periasamy, M. (1998) MEF2B is a component of a smooth musclespecific complex that binds an A/T-rich element important for smooth muscle myosin heavy chain gene expression. J. Biol. Chem. 273, 1511-1518
12. Deaton, R. A., Su, C., Valencia, T. G., and Grant, S. R. (2005) Transforming growth factor-beta1-induced expression of smooth muscle marker genes involves activation of PKN and p38 MAPK. J. Biol. Chem. 280, 31172-31181
13. Gregoire, S., Tremblay, A. M., Xiao, L., Yang, Q., Ma, K., Nie, J., Mao, Z., Wu, Z., Giguere, V., and Yang, X. J. (2006) Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation. J. Biol. Chem. 281, 4423-4433
14. Black, B. L., and Olson, E. N. (1998) Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu. Rev. Cell Dev. Biol. 14, 167-196
15. Firulli, A. B., Miano, J. M., Bi, W., Johnson, A. D., Casscells, W., Olson, E. N., and Schwarz, J. J. (1996) Myocyte enhancer binding factor-2 expression and activity in vascular smooth muscle cells: association with the activated phenotype. Circ. Res. 78, 196-204 (Pubitemid 26042838)
16. Wang, L., Fan, C., Topol, S. E., Topol, E. J., and Wang, Q. (2003) Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 302, 1578-1581
17. Lieb, W., Mayer, B., Konig, I. R., Borwitzky, I., Gotz, A., Kain, S., Hengstenberg, C., Linsel-Nitschke, P., Fischer, M., Doring, A., Wichmann, H. E., Meitinger, T., Kreutz, R., Ziegler, A., Schunkert, H., and Erdmann, J. (2008) Lack of association between the MEF2A gene and myocardial infarction. Circulation 117, 185-191
18. Prokunina, L., and Alarcon-Riquelme, M. E. (2004) Regulatory SNPs in complex diseases: their identification and functional validation. Expert Rev. Mol. Med. 6, 1-15
19. World Health Organization (1999) World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J. Hypertens. 17, 151-183
20. Oishi, Y., Manabe, I., Tobe, K., Tsushima, K., Shindo, T., Fujiu, K., Nishimura, G., Maemura, K., Yamauchi, T., Kubota, N., Suzuki, R., Kitamura, T., Akira, S., Kadowaki, T., and Nagai, R. (2005) Krüppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell. Metab. 1, 27-39
21. Manabe, I., and Owens, G. K. (2001) Recruitment of serum response factor and hyperacetylation of histones at smooth muscle-specific regulatory regions during differentiation of a novel P19-derived in vitro smooth muscle differentiation system. Circ. Res. 88, 1127-1134 (Pubitemid 34132512)
22. Manabe, I., and Owens, G. K. (2001) CArG elements control smooth muscle subtype-specific expression of smooth muscle myosin in vivo. J. Clin. Invest. 107, 823-834 (Pubitemid 32274035)
23. Pollock, R., and Treisman, R. (1991) Human SRF-related proteins: DNA-binding properties and potential regulatory targets. Genes Dev. 5, 2327-2341 (Pubitemid 21905921)
24. Mehta, P. K., and Griendling, K. K. (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 292, C82-C97
25. Kearney, M., Pieczek, A., Haley, L., Losordo, D. W., Andres, V., Schainfeld, R., Rosenfield, K., and Isner, J. M. (1997) Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 95, 1998-2002 (Pubitemid 27184264)
26. Clempus, R. E., and Griendling, K. K. (2006) Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc. Res. 71, 216-225
27. Ushio-Fukai, M., Alexander, R. W., Akers, M., and Griendling, K. K. (1998) p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J. Biol. Chem. 273, 15022-15029
28. Han, J., and Molkentin, J. D. (2000) Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology. Trends Cardiovasc. Med. 10, 19-22
29. Atkins, G. B., and Jain, M. K. (2007) Role of Krüppel-like transcription factors in endothelial biology. Circ. Res. 100, 1686-1695
30. Parmar, K. M., Larman, H. B., Dai, G., Zhang, Y., Wang, E. T., Moorthy, S. N., Kratz, J. R., Lin, Z., Jain, M. K., Gimbrone, M. A., Jr., and Garcia-Cardena, G. (2006) Integration of flow-dependent endothelial phenotypes by Krüppel-like factor 2. J. Clin. Invest. 116, 49-58
31. Kumar, A., Hoffman, T. A., Dericco, J., Naqvi, A., Jain, M. K., and Irani, K. (2009) Transcriptional repression of Krüppel-like factor-2 by the adaptor protein p66shc. FASEB J. 23, 4344-4352
32. Kumar, A., Lin, Z., Senbanerjee, S., and Jain, M. K. (2005) Tumor Necrosis factor alpha-mediated reduction of KLF2 is due to inhibition of MEF2 by NF-{kappa}B and histone deacetylases. Mol. Cell. Biol. 25, 5893-5903
33. Agarwal, A., Williams, G. H., and Fisher, N. D. (2005) Genetics of human hypertension. Trends Endocrinol. Metab. 16, 127-133
34. Oparil, S., Zaman, M. A., and Calhoun, D. A. (2003) Pathogenesis of hypertension. Ann. Intern. Med. 139, 761-776
35. Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678